<DOC>
	<DOC>NCT02143973</DOC>
	<brief_summary>The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.</brief_summary>
	<brief_title>Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Subject completed participation in the TR02 study Subject is currently receiving incenter hemodialysis at the time of consent Subject receiving or anticipated to be receiving nocturnal dialysis or home hemodialysis treatment during the study Subject received opiates on a daily basis during the 1 week prior to screening Other than the TR02 Study Drug, Subject received any investigational drug within 4 weeks prior to Screening Subject is a pregnant or lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Uremic</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Itch</keyword>
	<keyword>Chronic Itch</keyword>
	<keyword>Nalbuphine</keyword>
</DOC>